| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
982 | 704 | 430 | 103 | 0 |
| Cost of Revenue
|
-908 | -646 | -270 | -24 | 0 |
|
Gross Profit
|
74 | 58 | 160 | 79 | 0 |
| Selling, General and Administrative Expenses
|
-3,918 | -4,320 | -5,576 | -6,007 | -4,411 |
|
Research and Development Expenses
|
-2,866 | -2,653 | -2,310 | -3,062 | -1,742 |
| Other Income/Expense, Operating
|
-- | -- | -- | -- | 0 |
|
Operating Income/Expenses
|
-6,784 | -6,973 | -7,886 | -9,069 | -6,153 |
|
Total Operating Profit/Loss
|
-6,710 | -6,915 | -7,726 | -8,990 | -6,153 |
| Total Net Finance Income/Expense
|
6 | 29 | -6 | 50 | -9 |
| Net Investment Income
|
-- | -- | -- | 0 | 2 |
|
Rental Income
|
-- | -- | -- | 0 | 87 |
| Irregular Income/Expenses
|
-- | -- | -- | -- | 0 |
|
Other Income/Expense, Non-Operating
|
21 | 17 | 0 | -5 | 0 |
|
Non-Operating Income/Expenses, Total
|
27 | 46 | -6 | 45 | 80 |
|
Pretax Income
|
-6,683 | -6,869 | -7,732 | -8,945 | -6,073 |
|
Net Income from Continuing Operations
|
-6,683 | -6,869 | -7,732 | -8,945 | -6,073 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-6,683 | -6,869 | -7,732 | -8,945 | -6,073 |
|
Net Income after Non-Controlling/Minority Interests
|
-6,683 | -6,869 | -7,732 | -8,945 | -6,073 |
| Preferred/Other Stock Distribution
|
0 | -- | 0 | -77 | -180 |
|
Net Income Available to Common Stockholders
|
-6,683 | -6,869 | -7,732 | -9,022 | -6,253 |
|
Diluted Net Income Available to Common Stockholders
|
-6,683 | -6,869 | -7,732 | -9,022 | -6,253 |
| Basic EPS
|
-0.39 | -0.42 | -0.52 | -0.67 | -0.55 |
| Diluted EPS
|
-0.39 | -0.42 | -0.52 | -0.67 | -0.55 |
|
Basic Weighted Average Shares Outstanding
|
17,348.0090 | 16,517.1260 | 14,789.3320 | 13,455.6660 | 11,349.6100 |
|
Diluted Weighted Average Shares Outstanding
|
17,348.0090 | 16,517.1260 | 14,789.3320 | 13,455.6660 | 11,349.6100 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-6,689 | -6,898 | -7,726 | -8,995 | -6,064 |
|
EBITDA
|
-6,581 | -6,795 | -7,559 | -8,861 | -5,990 |
|
Normalized EBITDA
|
-4,738 | -4,785 | -5,157 | -5,400 | -4,961 |
|
Normalized Income
|
-4,840 | -4,859 | -5,330 | -5,484 | -5,044 |
12/31/2022 - 10/21/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade